It may have been inhibiting bacteria which causes too much de-conjugation of bile acids which would increase Tauro-Beta-Muricholic Acid. This acting as an FXR antagonist would allow normal function and bile circulation to resume in the liver. I think this is what is happening in CFS and that positive effects from antibiotics are due to adjustments in the gut.
@Bdeep86 I think your very interesting idea may be based on this
study. Note that tauro-beta-muricholic acid is a conjugated bile acid found primarily in mice and rats, and humans would seemingly only have very low levels of this that could potentially be increased from antibiotic treatment. ["Humans synthesize cholic acid (CA) and chenodeoxycholic acid (CDCA), whereas mice synthesize CA and β-muricholic acid (βMCA) (Russell, 2003)."]
So I'm not sure how much of an effect that increasing any endogenous tauro-βMCA might have, although that compound does have a fairly potent IC50 of 40 microM as a farnesoid X receptor (FXR) antagonist.
There are two very interesting additional things that I found from researching your idea, though:
The first, which is related to the hypothesis in my signature, is that there is a sphingosine-1-phosphate (S1P) receptor, S1PR2, in liver cells that is not only activated by S1P but also by conjugated bile acids including, for example, tauroursodeoxycholic acid (TUDCA).
Reference - this is a mouse study but the authors believe it applies to humans:
Conjugates of UDCA have been shown to activate the ERK1/2 and AKT signaling pathways in primary hepatocytes in culture (36, 37). The current data suggest that activation of these signaling pathways by TUDCA may be via the S1P2 [aka S1PR2] in primary hepatocytes (Fig. 4).
So the favorable antibiotic effect sometimes seen in ME/CFS, assuming it's due to an increase in conjugated bile acids, might actually potentially be due to increased agonism of the S1PR2 receptor.
Either S1PR2 agonism or FXR antagonism might theoretically increase mTORC1 activity and seemingly be favorable for the PDH complex impairment Fluge & Mella found.
However, the second thing I came across is that FXR appears to be very intimately involved with the production of ceramides. (See, for example,
reference #1 and
reference #2.) (Note: The second reference also mentions the use of caffeic acid phenethyl ester (CAPE), which might be a potential alternative to antibiotics for increasing levels of conjugated bile acids since it inhibits bacterial de-conjugation.)
Using FXR antagonists (or increasing their endogenous levels) would actually lower ceramide levels, and these have already been found to be low in ME/CFS in the
Naviaux study. So this would not seem compatible and not appear to be a good idea at first glance - unless the low ceramide levels are actually a favorable adaptation in ME/CFS.
Lastly, I haven't looked at it closely, but there is at least one interdependent relationship that has been found between FXR and S1PR2, and in this case activating FXR decreased the expression of S1PR2. (
Reference) I'm not sure how applicable this particular situation is to ME/CFS, though.
In sum, I'm not sure whether antagonism of FXR would be a good thing or not, I'm guessing not but who knows. In any event, I don't believe it would be occurring due to endogenous tauro-βMCA because this bile acid is probably not found in humans in large enough amounts to affect FXR. On the other hand, I suspect your idea about inhibition of bacterial de-conjugation being behind the favorable response to antibiotics seen in ME/CFS is probably correct.